FDA launches “Bad Ad” program to curb misleading drug promotions
The U.S. Food and Drug Administration (FDA) has launched an educational outreach program to encourage health care providers to report false and misleading advertisements of prescription medications.
The FDA’s “Bad Ad” program provides tips on recognizing false and misleading prescription drug ads and provides an easy avenue for reporting violations. The program covers prescription drug ads only, and does not pertain to ads for medical devices or over-the-counter drugs.
Common violations of FDA regulations on prescription drug marketing include ads that downplay or omit information about a risk; overstate a drug’s effectiveness; promote off-label (unapproved) uses; and state misleading comparisons with other drugs.
To learn more about the Bad Ad program, go to the FDA website.